Statin Use and Breast Cancer: Prospective Results From the Women's Health Initiative

Jane A Cauley; Anne McTiernan; Rebecca J Rodabough; Andrea LaCroix; Douglas C Bauer; Karen L Margolis; Electra D Paskett; Mara Z Vitolins; Curt D Furberg; Rowan T Chlebowski; Women's Hlth Initiative Res Grp

doi:10.1093/jnci/djj188

Back

Statin Use and Breast Cancer: Prospective Results From the Women's Health Initiative

Journal article

Open access

Statin Use and Breast Cancer: Prospective Results From the Women's Health Initiative

Jane A Cauley, Anne McTiernan, Rebecca J Rodabough, Andrea LaCroix, Douglas C Bauer, Karen L Margolis, Electra D Paskett, Mara Z Vitolins, Curt D Furberg, Rowan T Chlebowski, …

JNCI : Journal of the National Cancer Institute, Vol.98(10), pp.700-707

2006-05-17

DOI: https://doi.org/10.1093/jnci/djj188

PMID: 16705124

Abstract

Background: Despite experimental observations suggesting that 3-hydroxy-3-methylglutaryl coenzyme A inhibitors (statins) have antitumor activity, clinical studies have reached mixed conclusions about the relationship between statin use and breast cancer risk. Methods: To investigate associations between potency, duration of use, and type of statin used and risk of invasive breast cancer, we examined data for 156 351 postmenopausal women who were enrolled in the Women's Health Initiative. Information was collected on breast cancer risk factors and on the use of statins and other lipid-lowering drugs. Cox proportional hazards regression was used to calculate hazard ratios (HRs) with 95% confidence intervals (CIs). Statistical tests were two-sided. Results: Over an average follow-up of 6.7 years, 4383 invasive breast cancers were confirmed by medical record and pathology report review. Statins were used by 11 710 (7.5%) of the cohort. Breast cancer incidence was 4.09 per 1000 person-years (PY) among statin users and 4.28 per 1000 PY among nonusers. In multivariable models, the hazard ratio of breast cancer among users of any statin, compared with nonusers, was 0.91 (95% CI = 0.80 to 1.05, P = .20). There was no trend in risk by duration of statin use, with HR = 0.80 (95% CI = 0.63 to 1.03) for <1 year of use, HR = 0.99 (95% CI = 0.80 to 1.23) for 1–<3 years of use, and HR = 0.94 (95% CI = 0.75 to 1.18) for ≥3 years of use. Hydrophobic statins (i.e., simvastatin, lovastatin, and fluvastatin) were used by 8106 women, and their use was associated with an 18% lower breast cancer incidence (HR = 0.82, 95% CI = 0.70 to 0.97, P = .02). Use of other statins (i.e., pravastatin and atorvastatin) or nonstatin lipid-lowering agents was not associated with breast cancer incidence. Conclusions: Overall statin use was not associated with invasive breast cancer incidence. Our finding that use of hydrophobic statins may be associated with lower breast cancer incidence suggests possible within-class differences that warrant further evaluation.

Files and links (1)

url

https://doi.org/10.1093/jnci/djj188View

Published (Version of record) Open

Metrics

9 Record Views

150 Times Cited - Web of Science

See more details

InCites Highlights

These are selected metrics from InCites Benchmarking & Analytics tool, related to this output

Collaboration types: Domestic collaboration
Citation topics: 1 Clinical & Life Sciences; 1.68 Lipids; 1.68.236 Statins
Web Of Science research areas: Oncology
ESI research areas: Clinical Medicine

UN Sustainable Development Goals (SDGs)

This output has contributed to the advancement of the following goals:

Source: InCites

Details

Title: Statin Use and Breast Cancer: Prospective Results From the Women's Health Initiative
Creators: Jane A Cauley - : Department of Epidemiology, University of Pittsburgh, Pittsburgh, PA (JAC); Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, WA (AM, RJR, AL); Departments of Medicine and Epidemiology and Biostatistics, University of California at San Francisco, CA (DCB); Berman Center for Outcomes and Clinical Research, Hennepin County Medical Center, Minneapolis, MN (KLM); Comprehensive Cancer Center, School of Public Health, The Ohio State University, Columbus, OH (EDP); School of Medicine, Department of Public Health Sciences, Wake Forest University, Winston-Salem, NC (MZV, CDF); Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center, Torrance, CA (RTC)
Anne McTiernan - : Department of Epidemiology, University of Pittsburgh, Pittsburgh, PA (JAC); Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, WA (AM, RJR, AL); Departments of Medicine and Epidemiology and Biostatistics, University of California at San Francisco, CA (DCB); Berman Center for Outcomes and Clinical Research, Hennepin County Medical Center, Minneapolis, MN (KLM); Comprehensive Cancer Center, School of Public Health, The Ohio State University, Columbus, OH (EDP); School of Medicine, Department of Public Health Sciences, Wake Forest University, Winston-Salem, NC (MZV, CDF); Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center, Torrance, CA (RTC)
Rebecca J Rodabough - : Department of Epidemiology, University of Pittsburgh, Pittsburgh, PA (JAC); Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, WA (AM, RJR, AL); Departments of Medicine and Epidemiology and Biostatistics, University of California at San Francisco, CA (DCB); Berman Center for Outcomes and Clinical Research, Hennepin County Medical Center, Minneapolis, MN (KLM); Comprehensive Cancer Center, School of Public Health, The Ohio State University, Columbus, OH (EDP); School of Medicine, Department of Public Health Sciences, Wake Forest University, Winston-Salem, NC (MZV, CDF); Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center, Torrance, CA (RTC)
Andrea LaCroix - : Department of Epidemiology, University of Pittsburgh, Pittsburgh, PA (JAC); Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, WA (AM, RJR, AL); Departments of Medicine and Epidemiology and Biostatistics, University of California at San Francisco, CA (DCB); Berman Center for Outcomes and Clinical Research, Hennepin County Medical Center, Minneapolis, MN (KLM); Comprehensive Cancer Center, School of Public Health, The Ohio State University, Columbus, OH (EDP); School of Medicine, Department of Public Health Sciences, Wake Forest University, Winston-Salem, NC (MZV, CDF); Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center, Torrance, CA (RTC)
Douglas C Bauer - : Department of Epidemiology, University of Pittsburgh, Pittsburgh, PA (JAC); Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, WA (AM, RJR, AL); Departments of Medicine and Epidemiology and Biostatistics, University of California at San Francisco, CA (DCB); Berman Center for Outcomes and Clinical Research, Hennepin County Medical Center, Minneapolis, MN (KLM); Comprehensive Cancer Center, School of Public Health, The Ohio State University, Columbus, OH (EDP); School of Medicine, Department of Public Health Sciences, Wake Forest University, Winston-Salem, NC (MZV, CDF); Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center, Torrance, CA (RTC)
Karen L Margolis - : Department of Epidemiology, University of Pittsburgh, Pittsburgh, PA (JAC); Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, WA (AM, RJR, AL); Departments of Medicine and Epidemiology and Biostatistics, University of California at San Francisco, CA (DCB); Berman Center for Outcomes and Clinical Research, Hennepin County Medical Center, Minneapolis, MN (KLM); Comprehensive Cancer Center, School of Public Health, The Ohio State University, Columbus, OH (EDP); School of Medicine, Department of Public Health Sciences, Wake Forest University, Winston-Salem, NC (MZV, CDF); Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center, Torrance, CA (RTC)
Electra D Paskett - : Department of Epidemiology, University of Pittsburgh, Pittsburgh, PA (JAC); Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, WA (AM, RJR, AL); Departments of Medicine and Epidemiology and Biostatistics, University of California at San Francisco, CA (DCB); Berman Center for Outcomes and Clinical Research, Hennepin County Medical Center, Minneapolis, MN (KLM); Comprehensive Cancer Center, School of Public Health, The Ohio State University, Columbus, OH (EDP); School of Medicine, Department of Public Health Sciences, Wake Forest University, Winston-Salem, NC (MZV, CDF); Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center, Torrance, CA (RTC)
Mara Z Vitolins - : Department of Epidemiology, University of Pittsburgh, Pittsburgh, PA (JAC); Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, WA (AM, RJR, AL); Departments of Medicine and Epidemiology and Biostatistics, University of California at San Francisco, CA (DCB); Berman Center for Outcomes and Clinical Research, Hennepin County Medical Center, Minneapolis, MN (KLM); Comprehensive Cancer Center, School of Public Health, The Ohio State University, Columbus, OH (EDP); School of Medicine, Department of Public Health Sciences, Wake Forest University, Winston-Salem, NC (MZV, CDF); Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center, Torrance, CA (RTC)
Curt D Furberg - : Department of Epidemiology, University of Pittsburgh, Pittsburgh, PA (JAC); Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, WA (AM, RJR, AL); Departments of Medicine and Epidemiology and Biostatistics, University of California at San Francisco, CA (DCB); Berman Center for Outcomes and Clinical Research, Hennepin County Medical Center, Minneapolis, MN (KLM); Comprehensive Cancer Center, School of Public Health, The Ohio State University, Columbus, OH (EDP); School of Medicine, Department of Public Health Sciences, Wake Forest University, Winston-Salem, NC (MZV, CDF); Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center, Torrance, CA (RTC)
Rowan T Chlebowski - : Department of Epidemiology, University of Pittsburgh, Pittsburgh, PA (JAC); Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, WA (AM, RJR, AL); Departments of Medicine and Epidemiology and Biostatistics, University of California at San Francisco, CA (DCB); Berman Center for Outcomes and Clinical Research, Hennepin County Medical Center, Minneapolis, MN (KLM); Comprehensive Cancer Center, School of Public Health, The Ohio State University, Columbus, OH (EDP); School of Medicine, Department of Public Health Sciences, Wake Forest University, Winston-Salem, NC (MZV, CDF); Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center, Torrance, CA (RTC)
Women's Hlth Initiative Res Grp
Publication Details: JNCI : Journal of the National Cancer Institute, Vol.98(10), pp.700-707
Publisher: Oxford University Press
Language: English
Resource Type: Journal article
PMID: 16705124
Record Identifier: 991031597482902976